Drugs interactions for Glyxambi®

  • 127 Major drug interactions (including ingredients like Abametapir, Abemaciclib, Acalabrutinib)
  • 999 Moderate drug interactions (including ingredients like Abatacept, Abiraterone, Abrocitinib)
  • 183 Minor drug interactions (including ingredients like Abaloparatide, Acetazolamide, Acetyl sulfisoxazole)
1309 interactions for Glyxambi®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Glyxambi®.
Abametapir
The serum concentration of Linagliptin can be increased when it is combined with Abametapir.
Abemaciclib
The serum concentration of Abemaciclib can be increased when it is combined with Linagliptin.
Acalabrutinib
The metabolism of Acalabrutinib can be decreased when combined with Linagliptin.
Alectinib
The metabolism of Alectinib can be decreased when combined with Linagliptin.
Alpelisib
The metabolism of Alpelisib can be decreased when combined with Linagliptin.
Aminophylline
The metabolism of Aminophylline can be decreased when combined with Linagliptin.
Amiodarone
The metabolism of Linagliptin can be decreased when combined with Amiodarone.
Atazanavir
The metabolism of Linagliptin can be decreased when combined with Atazanavir.
Axitinib
The serum concentration of Axitinib can be increased when it is combined with Linagliptin.
Bendamustine
The serum concentration of Bendamustine can be increased when it is combined with Linagliptin.
Bicalutamide
The metabolism of Bicalutamide can be decreased when combined with Linagliptin.
Binimetinib
The serum concentration of Binimetinib can be increased when it is combined with Linagliptin.
Bortezomib
The serum concentration of Bortezomib can be increased when it is combined with Linagliptin.
Brigatinib
The metabolism of Brigatinib can be decreased when combined with Linagliptin.
Busulfan
The metabolism of Busulfan can be decreased when combined with Linagliptin.
Cabazitaxel
The metabolism of Cabazitaxel can be decreased when combined with Linagliptin.
Cabergoline
The serum concentration of Cabergoline can be increased when it is combined with Linagliptin.
Carbamazepine
The metabolism of Carbamazepine can be decreased when combined with Linagliptin.
Carfilzomib
The serum concentration of Carfilzomib can be increased when it is combined with Linagliptin.
Cariprazine
The metabolism of Cariprazine can be decreased when combined with Linagliptin.
Ceritinib
The serum concentration of Ceritinib can be increased when it is combined with Linagliptin.
Cisplatin
The serum concentration of Cisplatin can be increased when it is combined with Linagliptin.
Clarithromycin
The metabolism of Linagliptin can be decreased when combined with Clarithromycin.
Clofarabine
The serum concentration of Clofarabine can be increased when it is combined with Linagliptin.
Clomipramine
The metabolism of Clomipramine can be decreased when combined with Linagliptin.
Clonidine
The metabolism of Clonidine can be decreased when combined with Linagliptin.
Conivaptan
The metabolism of Linagliptin can be decreased when combined with Conivaptan.
Copanlisib
The metabolism of Copanlisib can be decreased when combined with Linagliptin.
Crizotinib
The serum concentration of Crizotinib can be increased when it is combined with Linagliptin.
Curcumin
The metabolism of Linagliptin can be decreased when combined with Curcumin.
Cyclophosphamide
The metabolism of Cyclophosphamide can be decreased when combined with Linagliptin.
Cyclosporine
The serum concentration of Cyclosporine can be increased when it is combined with Linagliptin.
Dacomitinib
The serum concentration of Dacomitinib can be increased when it is combined with Linagliptin.
Dactinomycin
The serum concentration of Dactinomycin can be increased when it is combined with Linagliptin.
Dalfampridine
The serum concentration of Dalfampridine can be increased when it is combined with Linagliptin.
Danazol
The metabolism of Linagliptin can be decreased when combined with Danazol.
Darunavir
The metabolism of Linagliptin can be decreased when combined with Darunavir.
Dasatinib
The serum concentration of Dasatinib can be increased when it is combined with Linagliptin.
Defactinib
The serum concentration of Defactinib can be increased when it is combined with Linagliptin.
Dihydroergotamine
The metabolism of Dihydroergotamine can be decreased when combined with Linagliptin.
Docetaxel
The metabolism of Docetaxel can be decreased when combined with Linagliptin.
Dofetilide
The metabolism of Dofetilide can be decreased when combined with Linagliptin.
Dronedarone
The metabolism of Dronedarone can be decreased when combined with Linagliptin.
Efavirenz
The metabolism of Linagliptin can be decreased when combined with Efavirenz.
Elacestrant
The serum concentration of Elacestrant can be increased when it is combined with Linagliptin.
Eliglustat
The metabolism of Eliglustat can be decreased when combined with Linagliptin.
Elvitegravir
The metabolism of Linagliptin can be decreased when combined with Elvitegravir.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Linagliptin.
Entrectinib
The metabolism of Entrectinib can be decreased when combined with Linagliptin.
Ergotamine
The metabolism of Linagliptin can be decreased when combined with Ergotamine.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Linagliptin.
Etoposide
The serum concentration of Etoposide can be increased when it is combined with Linagliptin.
Flibanserin
The metabolism of Flibanserin can be decreased when combined with Linagliptin.
Gemcitabine
The serum concentration of Gemcitabine can be increased when it is combined with Linagliptin.
Gentamicin
The serum concentration of Gentamicin can be increased when it is combined with Linagliptin.
Idelalisib
The metabolism of Idelalisib can be decreased when combined with Linagliptin.
Ifosfamide
The metabolism of Ifosfamide can be decreased when combined with Linagliptin.
Imipramine
The serum concentration of Imipramine can be increased when it is combined with Linagliptin.
Indinavir
The metabolism of Linagliptin can be decreased when combined with Indinavir.
Infigratinib
The metabolism of Infigratinib can be decreased when combined with Linagliptin.
Irinotecan
The metabolism of Irinotecan can be decreased when combined with Linagliptin.
Itraconazole
The metabolism of Linagliptin can be decreased when combined with Itraconazole.
Ivabradine
The metabolism of Ivabradine can be decreased when combined with Linagliptin.
Ixabepilone
The metabolism of Ixabepilone can be decreased when combined with Linagliptin.
Ixazomib
The metabolism of Ixazomib can be decreased when combined with Linagliptin.
Ketoconazole
The metabolism of Linagliptin can be decreased when combined with Ketoconazole.
Levoketoconazole
The metabolism of Linagliptin can be decreased when combined with Levoketoconazole.
Lomitapide
The metabolism of Lomitapide can be decreased when combined with Linagliptin.
Lonafarnib
The metabolism of Linagliptin can be decreased when combined with Lonafarnib.
Lopinavir
The metabolism of Linagliptin can be decreased when combined with Lopinavir.
Methimazole
The metabolism of Linagliptin can be decreased when combined with Methimazole.
Methotrexate
The metabolism of Methotrexate can be decreased when combined with Linagliptin.
Midostaurin
The metabolism of Linagliptin can be decreased when combined with Midostaurin.
Mitotane
The metabolism of Linagliptin can be increased when combined with Mitotane.
Nefazodone
The metabolism of Linagliptin can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Linagliptin can be decreased when combined with Nelfinavir.
Neratinib
The metabolism of Neratinib can be decreased when combined with Linagliptin.
Nilotinib
The metabolism of Linagliptin can be decreased when combined with Nilotinib.
Nortriptyline
The serum concentration of Nortriptyline can be increased when it is combined with Linagliptin.
Omaveloxolone
The serum concentration of Omaveloxolone can be increased when it is combined with Linagliptin.
Osimertinib
The serum concentration of Osimertinib can be increased when it is combined with Linagliptin.
Oxaliplatin
The serum concentration of Oxaliplatin can be increased when it is combined with Linagliptin.
Paclitaxel
The metabolism of Paclitaxel can be decreased when combined with Linagliptin.
Pacritinib
The serum concentration of Pacritinib can be increased when it is combined with Linagliptin.
Palbociclib
The metabolism of Palbociclib can be decreased when combined with Linagliptin.
Panobinostat
The serum concentration of Panobinostat can be increased when it is combined with Linagliptin.
Pentobarbital
The metabolism of Linagliptin can be increased when combined with Pentobarbital.
Pexidartinib
The metabolism of Pexidartinib can be decreased when combined with Linagliptin.
Phenobarbital
The metabolism of Linagliptin can be increased when combined with Phenobarbital.
Pimavanserin
The metabolism of Pimavanserin can be increased when combined with Linagliptin.
Pimozide
The metabolism of Pimozide can be decreased when combined with Linagliptin.
Pomalidomide
The serum concentration of Pomalidomide can be increased when it is combined with Linagliptin.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Linagliptin.
Posaconazole
The metabolism of Linagliptin can be decreased when combined with Posaconazole.
Pretomanid
The serum concentration of Pretomanid can be increased when it is combined with Linagliptin.
Primidone
The metabolism of Linagliptin can be increased when combined with Primidone.
Procainamide
The serum concentration of Procainamide can be increased when it is combined with Linagliptin.
Quinidine
The serum concentration of Quinidine can be increased when it is combined with Linagliptin.
Regorafenib
The serum concentration of Regorafenib can be increased when it is combined with Linagliptin.
Ribociclib
The metabolism of Linagliptin can be decreased when combined with Ribociclib.
Rifapentine
The metabolism of Linagliptin can be increased when combined with Rifapentine.
Rimegepant
The serum concentration of Rimegepant can be increased when it is combined with Linagliptin.
Romidepsin
The serum concentration of Romidepsin can be increased when it is combined with Linagliptin.
Ruxolitinib
The metabolism of Ruxolitinib can be decreased when combined with Linagliptin.
Saquinavir
The metabolism of Linagliptin can be decreased when combined with Saquinavir.
Selumetinib
The serum concentration of Selumetinib can be increased when it is combined with Linagliptin.
Silodosin
The excretion of Silodosin can be decreased when combined with Linagliptin.
Siponimod
The risk or severity of adverse effects can be increased when Linagliptin is combined with Siponimod.
Sirolimus
The serum concentration of Sirolimus can be increased when it is combined with Linagliptin.
Sorafenib
The metabolism of Sorafenib can be decreased when combined with Linagliptin.
Sunitinib
The metabolism of Sunitinib can be decreased when combined with Linagliptin.
Tamoxifen
The metabolism of Tamoxifen can be decreased when combined with Linagliptin.
Telithromycin
The metabolism of Linagliptin can be decreased when combined with Telithromycin.
Temsirolimus
The serum concentration of Temsirolimus can be increased when it is combined with Linagliptin.
Teniposide
The metabolism of Teniposide can be decreased when combined with Linagliptin.
Tepotinib
The serum concentration of Tepotinib can be increased when it is combined with Linagliptin.
Theophylline
The metabolism of Theophylline can be decreased when combined with Linagliptin.
Thiotepa
The metabolism of Thiotepa can be decreased when combined with Linagliptin.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Linagliptin.
Trabectedin
The metabolism of Trabectedin can be decreased when combined with Linagliptin.
Trastuzumab emtansine
The serum concentration of Trastuzumab emtansine can be increased when it is combined with Linagliptin.
Trimipramine
The serum concentration of Trimipramine can be increased when it is combined with Linagliptin.
Vandetanib
The metabolism of Vandetanib can be decreased when combined with Linagliptin.
Venetoclax
The serum concentration of Venetoclax can be increased when it is combined with Linagliptin.
Vinblastine
The serum concentration of Vinblastine can be increased when it is combined with Linagliptin.
Vinorelbine
The metabolism of Vinorelbine can be decreased when combined with Linagliptin.
Voriconazole
The metabolism of Linagliptin can be decreased when combined with Voriconazole.
Abatacept
The metabolism of Linagliptin can be increased when combined with Abatacept.
Abiraterone
The metabolism of Linagliptin can be decreased when combined with Abiraterone.
Abrocitinib
The serum concentration of Linagliptin can be increased when it is combined with Abrocitinib.
Acarbose
The risk or severity of hypoglycemia can be increased when Acarbose is combined with Linagliptin.
Acarbose
Empagliflozin may increase the hypoglycemic activities of Acarbose.
Acebutolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Acebutolol.
Acebutolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acebutolol.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Linagliptin.
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Linagliptin.
Acetazolamide
The metabolism of Linagliptin can be decreased when combined with Acetazolamide.
Acetylcholine
The risk or severity of adverse effects can be increased when Linagliptin is combined with Acetylcholine.
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Linagliptin.
Acetylsalicylic acid
The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Empagliflozin.
Acyclovir
The risk or severity of adverse effects can be increased when Linagliptin is combined with Acyclovir.
Adagrasib
The metabolism of Adagrasib can be decreased when combined with Linagliptin.
Adalimumab
The metabolism of Linagliptin can be increased when combined with Adalimumab.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Linagliptin.
Albendazole
The metabolism of Albendazole can be decreased when combined with Linagliptin.
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Linagliptin.
Alclometasone
The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Empagliflozin.
Aldesleukin
The metabolism of Linagliptin can be decreased when combined with Aldesleukin.
Alfentanil
The metabolism of Alfentanil can be decreased when combined with Linagliptin.
Alfuzosin
The metabolism of Alfuzosin can be decreased when combined with Linagliptin.
Aliskiren
The metabolism of Aliskiren can be decreased when combined with Linagliptin.
Almotriptan
The metabolism of Almotriptan can be decreased when combined with Linagliptin.
Alogliptin
The metabolism of Alogliptin can be decreased when combined with Linagliptin.
Alogliptin
Empagliflozin may increase the hypoglycemic activities of Alogliptin.
Alosetron
The metabolism of Alosetron can be decreased when combined with Linagliptin.
Alprazolam
The metabolism of Alprazolam can be decreased when combined with Linagliptin.
Alteplase
The risk or severity of angioedema can be increased when Alteplase is combined with Linagliptin.
Amantadine
The serum concentration of Linagliptin can be increased when it is combined with Amantadine.
Ambrisentan
The metabolism of Ambrisentan can be decreased when combined with Linagliptin.
Amcinonide
The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Linagliptin.
Amcinonide
The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Empagliflozin.
Amiloride
The serum concentration of Linagliptin can be increased when it is combined with Amiloride.
Aminosalicylic acid
Aminosalicylic acid may increase the hypoglycemic activities of Linagliptin.
Aminosalicylic acid
Aminosalicylic acid may increase the hypoglycemic activities of Empagliflozin.
Amiodarone
The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Empagliflozin.
Amitriptyline
Amitriptyline may decrease the hypoglycemic activities of Linagliptin.
Amitriptyline
Amitriptyline may decrease the hypoglycemic activities of Empagliflozin.
Amlodipine
The metabolism of Amlodipine can be decreased when combined with Linagliptin.
Amlodipine
The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Empagliflozin.
Amobarbital
The metabolism of Linagliptin can be increased when combined with Amobarbital.
Amobarbital
Amobarbital may increase the hypotensive activities of Empagliflozin.
Amoxapine
Amoxapine may decrease the hypoglycemic activities of Linagliptin.
Amoxapine
Amoxapine may decrease the hypoglycemic activities of Empagliflozin.
Anakinra
The metabolism of Linagliptin can be increased when combined with Anakinra.
Antipyrine
The metabolism of Antipyrine can be decreased when combined with Linagliptin.
Apalutamide
The serum concentration of Linagliptin can be decreased when it is combined with Apalutamide.
Apixaban
The metabolism of Apixaban can be decreased when combined with Linagliptin.
Apremilast
The metabolism of Linagliptin can be increased when combined with Apremilast.
Aprepitant
The metabolism of Linagliptin can be decreased when combined with Aprepitant.
Aripiprazole
The metabolism of Aripiprazole can be decreased when combined with Linagliptin.
Aripiprazole
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Aripiprazole.
Aripiprazole lauroxil
The metabolism of Aripiprazole lauroxil can be decreased when combined with Linagliptin.
Armodafinil
The metabolism of Linagliptin can be increased when combined with Armodafinil.
Arsenic trioxide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Arsenic trioxide.
Arsenic trioxide
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Arsenic trioxide.
Artemether
The metabolism of Artemether can be decreased when combined with Linagliptin.
Articaine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Articaine.
Articaine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.
Asciminib
The serum concentration of Linagliptin can be increased when it is combined with Asciminib.
Asenapine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Asenapine.
Asenapine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.
Asunaprevir
The metabolism of Asunaprevir can be decreased when combined with Linagliptin.
Atazanavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.
Atenolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Atenolol.
Atenolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Atenolol.
Atogepant
The metabolism of Atogepant can be decreased when combined with Linagliptin.
Atorvastatin
The metabolism of Atorvastatin can be decreased when combined with Linagliptin.
Atovaquone
The metabolism of Atovaquone can be decreased when combined with Linagliptin.
Avacopan
The metabolism of Avacopan can be decreased when combined with Linagliptin.
Avanafil
The metabolism of Avanafil can be decreased when combined with Linagliptin.
Avapritinib
The metabolism of Avapritinib can be decreased when combined with Linagliptin.
Avatrombopag
The metabolism of Avatrombopag can be decreased when combined with Linagliptin.
Avutometinib
The metabolism of Avutometinib can be decreased when combined with Linagliptin.
Azelastine
The metabolism of Azelastine can be decreased when combined with Linagliptin.
Azilsartan medoxomil
The risk or severity of angioedema can be increased when Azilsartan medoxomil is combined with Linagliptin.
Azithromycin
The metabolism of Azithromycin can be decreased when combined with Linagliptin.
Baclofen
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Baclofen.
Baclofen
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Baclofen.
Balsalazide
Balsalazide may increase the hypoglycemic activities of Linagliptin.
Balsalazide
Balsalazide may increase the hypoglycemic activities of Empagliflozin.
Baricitinib
The metabolism of Baricitinib can be decreased when combined with Linagliptin.
Beclomethasone dipropionate
The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Linagliptin.
Beclomethasone dipropionate
The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Empagliflozin.
Bedaquiline
The metabolism of Bedaquiline can be decreased when combined with Linagliptin.
Belinostat
The serum concentration of Belinostat can be increased when it is combined with Linagliptin.
Belumosudil
The metabolism of Belumosudil can be decreased when combined with Linagliptin.
Benazepril
The risk or severity of hypoglycemia can be increased when Benazepril is combined with Linagliptin.
Benazepril
The risk or severity of hypoglycemia can be increased when Benazepril is combined with Empagliflozin.
Bendroflumethiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bendroflumethiazide.
Benzphetamine
The metabolism of Benzphetamine can be decreased when combined with Linagliptin.
Berotralstat
The serum concentration of Berotralstat can be increased when it is combined with Linagliptin.
Betamethasone
The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Linagliptin.
Betamethasone
The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Empagliflozin.
Betaxolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Betaxolol.
Betaxolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Betaxolol.
Betrixaban
The serum concentration of Betrixaban can be increased when it is combined with Linagliptin.
Bexagliflozin
Bexagliflozin may increase the hypoglycemic activities of Linagliptin.
Bexagliflozin
Empagliflozin may increase the hypoglycemic activities of Bexagliflozin.
Bexarotene
The metabolism of Linagliptin can be increased when combined with Bexarotene.
Bictegravir
The metabolism of Bictegravir can be decreased when combined with Linagliptin.
Bimekizumab
The metabolism of Linagliptin can be increased when combined with Bimekizumab.
Bismuth subsalicylate
Bismuth subsalicylate may increase the hypoglycemic activities of Linagliptin.
Bismuth subsalicylate
Bismuth subsalicylate may increase the hypoglycemic activities of Empagliflozin.
Bisoprolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Bisoprolol.
Bisoprolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bisoprolol.
Bosentan
The metabolism of Linagliptin can be increased when combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Linagliptin.
Brentuximab vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Linagliptin.
Brexpiprazole
The metabolism of Brexpiprazole can be decreased when combined with Linagliptin.
Brexpiprazole
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.
Brivaracetam
The metabolism of Brivaracetam can be decreased when combined with Linagliptin.
Bromocriptine
The metabolism of Bromocriptine can be decreased when combined with Linagliptin.
Bromocriptine
Empagliflozin may increase the hypoglycemic activities of Bromocriptine.
Budesonide
The risk or severity of hyperglycemia can be increased when Budesonide is combined with Linagliptin.
Budesonide
The risk or severity of hyperglycemia can be increased when Budesonide is combined with Empagliflozin.
Bumetanide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Bumetanide.
Bupivacaine
The metabolism of Bupivacaine can be decreased when combined with Linagliptin.
Buprenorphine
The metabolism of Buprenorphine can be decreased when combined with Linagliptin.
Bupropion
The excretion of Linagliptin can be decreased when combined with Bupropion.
Buspirone
The metabolism of Buspirone can be decreased when combined with Linagliptin.
Butalbital
The metabolism of Linagliptin can be increased when combined with Butalbital.
Butalbital
Butalbital may increase the hypotensive activities of Empagliflozin.
Cabozantinib
The metabolism of Cabozantinib can be decreased when combined with Linagliptin.
Calcitriol
The metabolism of Calcitriol can be decreased when combined with Linagliptin.
Canagliflozin
Canagliflozin may increase the hypoglycemic activities of Linagliptin.
Canagliflozin
Canagliflozin may increase the hypoglycemic activities of Empagliflozin.
Canakinumab
The metabolism of Linagliptin can be increased when combined with Canakinumab.
Cannabidiol
The metabolism of Cannabidiol can be decreased when combined with Linagliptin.
Capivasertib
The serum concentration of Capivasertib can be increased when it is combined with Linagliptin.
Capmatinib
The metabolism of Capmatinib can be decreased when combined with Linagliptin.
Capsaicin
The metabolism of Linagliptin can be decreased when combined with Capsaicin.
Captopril
The risk or severity of angioedema can be increased when Linagliptin is combined with Captopril.
Captopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Captopril.
Carvedilol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Carvedilol.
Carvedilol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Carvedilol.
Celecoxib
The metabolism of Celecoxib can be decreased when combined with Linagliptin.
Cenobamate
The serum concentration of Linagliptin can be decreased when it is combined with Cenobamate.
Cephalexin
The metabolism of Cephalexin can be decreased when combined with Linagliptin.
Ceritinib
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.
Certolizumab pegol
The metabolism of Linagliptin can be increased when combined with Certolizumab pegol.
Cevimeline
The metabolism of Cevimeline can be decreased when combined with Linagliptin.
Chenodeoxycholic acid
The metabolism of Chenodeoxycholic acid can be decreased when combined with Linagliptin.
Chloramphenicol
The metabolism of Linagliptin can be decreased when combined with Chloramphenicol.
Chloroquine
The metabolism of Chloroquine can be decreased when combined with Linagliptin.
Chlorothiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide.
Chlorpheniramine
The metabolism of Chlorpheniramine can be decreased when combined with Linagliptin.
Chlorpromazine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorpromazine.
Chlorpromazine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Chlorpromazine.
Chlorthalidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorthalidone.
Chlorzoxazone
The metabolism of Chlorzoxazone can be decreased when combined with Linagliptin.
Cholecalciferol
The metabolism of Cholecalciferol can be decreased when combined with Linagliptin.
Choline
The serum concentration of Linagliptin can be increased when it is combined with Choline.
Choline salicylate
Choline salicylate may increase the hypoglycemic activities of Linagliptin.
Choline salicylate
Choline salicylate may increase the hypoglycemic activities of Empagliflozin.
Ciclesonide
The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Linagliptin.
Ciclesonide
The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Empagliflozin.
Cilostazol
The metabolism of Cilostazol can be decreased when combined with Linagliptin.
Cimetidine
The serum concentration of Linagliptin can be increased when it is combined with Cimetidine.
Cinacalcet
The metabolism of Cinacalcet can be decreased when combined with Linagliptin.
Ciprofloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Ciprofloxacin.
Ciprofloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ciprofloxacin.
Citalopram
The risk or severity of hypoglycemia can be increased when Citalopram is combined with Linagliptin.
Citalopram
The risk or severity of hypoglycemia can be increased when Citalopram is combined with Empagliflozin.
Clevidipine
The metabolism of Clevidipine can be decreased when combined with Linagliptin.
Clevidipine
The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Empagliflozin.
Clindamycin
The metabolism of Clindamycin can be decreased when combined with Linagliptin.
Clobazam
The metabolism of Clobazam can be decreased when combined with Linagliptin.
Clobetasol propionate
The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Linagliptin.
Clobetasol propionate
The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Empagliflozin.
Clocortolone
The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Linagliptin.
Clocortolone
The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Empagliflozin.
Clomifene
The serum concentration of Clomifene can be increased when it is combined with Linagliptin.
Clomipramine
Clomipramine may decrease the hypoglycemic activities of Empagliflozin.
Clonazepam
The metabolism of Clonazepam can be decreased when combined with Linagliptin.
Clopidogrel
The metabolism of Clopidogrel can be decreased when combined with Linagliptin.
Clorazepic acid
The metabolism of Clorazepic acid can be decreased when combined with Linagliptin.
Clozapine
The serum concentration of Clozapine can be increased when it is combined with Linagliptin.
Clozapine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Clozapine.
Cobicistat
The metabolism of Cobicistat can be decreased when combined with Linagliptin.
Cobimetinib
The metabolism of Cobimetinib can be decreased when combined with Linagliptin.
Codeine
The metabolism of Codeine can be decreased when combined with Linagliptin.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Linagliptin.
Conjugated estrogens
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Conjugated estrogens.
Conjugated estrogens
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Conjugated estrogens.
Corticotropin
The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Linagliptin.
Corticotropin
The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Empagliflozin.
Cortisone acetate
The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Linagliptin.
Cortisone acetate
The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Empagliflozin.
Crinecerfont
The metabolism of Crinecerfont can be decreased when combined with Linagliptin.
Cyclobenzaprine
The metabolism of Cyclobenzaprine can be decreased when combined with Linagliptin.
Cytarabine
The risk or severity of adverse effects can be increased when Linagliptin is combined with Cytarabine.
Dabigatran etexilate
The serum concentration of Dabigatran etexilate can be increased when it is combined with Linagliptin.
Dabrafenib
The serum concentration of Linagliptin can be decreased when it is combined with Dabrafenib.
Dabrafenib
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.
Danazol
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Danazol.
Danicopan
The serum concentration of Linagliptin can be increased when it is combined with Danicopan.
Dapagliflozin
Dapagliflozin may increase the hypoglycemic activities of Linagliptin.
Dapagliflozin
Dapagliflozin may increase the hypoglycemic activities of Empagliflozin.
Dapsone
The metabolism of Dapsone can be decreased when combined with Linagliptin.
Daptomycin
The serum concentration of Daptomycin can be increased when it is combined with Linagliptin.
Daridorexant
The metabolism of Daridorexant can be decreased when combined with Linagliptin.
Darifenacin
The metabolism of Darifenacin can be decreased when combined with Linagliptin.
Darolutamide
The metabolism of Darolutamide can be decreased when combined with Linagliptin.
Darunavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Darunavir.
Dasabuvir
The metabolism of Dasabuvir can be decreased when combined with Linagliptin.
Daunorubicin
The metabolism of Linagliptin can be decreased when combined with Daunorubicin.
Deferasirox
The metabolism of Linagliptin can be increased when combined with Deferasirox.
Deflazacort
The serum concentration of Deflazacort can be increased when it is combined with Linagliptin.
Deflazacort
The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Empagliflozin.
Delafloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Delafloxacin.
Delafloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Delafloxacin.
Desipramine
Desipramine may decrease the hypoglycemic activities of Linagliptin.
Desipramine
Desipramine may decrease the hypoglycemic activities of Empagliflozin.
Desogestrel
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Desogestrel.
Desogestrel
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Desogestrel.
Desonide
The risk or severity of hyperglycemia can be increased when Desonide is combined with Linagliptin.
Desonide
The risk or severity of hyperglycemia can be increased when Desonide is combined with Empagliflozin.
Desoximetasone
The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Linagliptin.
Desoximetasone
The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Empagliflozin.
Desvenlafaxine
The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Linagliptin.
Desvenlafaxine
The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Empagliflozin.
Deuruxolitinib
The metabolism of Deuruxolitinib can be decreased when combined with Linagliptin.
Deutetrabenazine
The metabolism of Deutetrabenazine can be decreased when combined with Linagliptin.
Deutivacaftor
The serum concentration of Linagliptin can be increased when it is combined with Deutivacaftor.
Dexamethasone
The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Linagliptin.
Dexamethasone
The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Empagliflozin.
Dexamethasone acetate
The serum concentration of Linagliptin can be decreased when it is combined with Dexamethasone acetate.
Dexamethasone acetate
The risk or severity of hyperglycemia can be increased when Dexamethasone acetate is combined with Empagliflozin.
Dexchlorpheniramine maleate
The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Linagliptin.
Dexlansoprazole
The metabolism of Dexlansoprazole can be decreased when combined with Linagliptin.
Dextromethorphan
The metabolism of Dextromethorphan can be decreased when combined with Linagliptin.
Dextropropoxyphene
The metabolism of Dextropropoxyphene can be decreased when combined with Linagliptin.
Diazepam
The metabolism of Diazepam can be decreased when combined with Linagliptin.
Diazoxide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Diazoxide.
Diazoxide
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Diazoxide.
Diclofenac
The metabolism of Diclofenac can be decreased when combined with Linagliptin.
Dicloxacillin
The metabolism of Linagliptin can be increased when combined with Dicloxacillin.
Dienogest
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Dienogest.
Dienogest
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dienogest.
Diflorasone
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Linagliptin.
Diflorasone
The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Empagliflozin.
Diflunisal
Diflunisal may increase the hypoglycemic activities of Linagliptin.
Diflunisal
Diflunisal may increase the hypoglycemic activities of Empagliflozin.
Difluprednate
The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Linagliptin.
Difluprednate
The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Empagliflozin.
Digoxin
Linagliptin may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydro-alpha-ergocryptine
The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Linagliptin.
Dihydrocodeine
The metabolism of Dihydrocodeine can be decreased when combined with Linagliptin.
Dihydroergocornine
The metabolism of Dihydroergocornine can be decreased when combined with Linagliptin.
Dihydroergocristine
The metabolism of Dihydroergocristine can be decreased when combined with Linagliptin.
Diltiazem
The metabolism of Linagliptin can be decreased when combined with Diltiazem.
Diltiazem
The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Empagliflozin.
Dimethyl sulfoxide
The metabolism of Linagliptin can be decreased when combined with Dimethyl sulfoxide.
Dinoprostone
The serum concentration of Linagliptin can be increased when it is combined with Dinoprostone.
Diosmin
The serum concentration of Linagliptin can be increased when it is combined with Diosmin.
Diphenhydramine
The serum concentration of Linagliptin can be increased when it is combined with Diphenhydramine.
Disopyramide
The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Linagliptin.
Disopyramide
Empagliflozin may increase the hypoglycemic activities of Disopyramide.
Disulfiram
The metabolism of Disulfiram can be decreased when combined with Linagliptin.
Dolasetron
The metabolism of Dolasetron can be decreased when combined with Linagliptin.
Dolutegravir
The serum concentration of Dolutegravir can be increased when it is combined with Linagliptin.
Donepezil
The metabolism of Donepezil can be decreased when combined with Linagliptin.
Dopamine
The serum concentration of Linagliptin can be increased when it is combined with Dopamine.
Doravirine
The metabolism of Doravirine can be decreased when combined with Linagliptin.
Doxazosin
The metabolism of Doxazosin can be decreased when combined with Linagliptin.
Doxepin
Doxepin may decrease the hypoglycemic activities of Linagliptin.
Doxepin
Doxepin may decrease the hypoglycemic activities of Empagliflozin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Linagliptin.
Dronabinol
The serum concentration of Dronabinol can be increased when it is combined with Linagliptin.
Drospirenone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Drospirenone.
Dulaglutide
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Dulaglutide.
Dulaglutide
Empagliflozin may increase the hypoglycemic activities of Dulaglutide.
Duloxetine
The risk or severity of hypoglycemia can be increased when Duloxetine is combined with Linagliptin.
Duvelisib
The metabolism of Duvelisib can be decreased when combined with Linagliptin.
Echinacea
The metabolism of Linagliptin can be increased when combined with Echinacea.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Linagliptin.
Elafibranor
The metabolism of Linagliptin can be increased when combined with Elafibranor.
Elagolix
The serum concentration of Elagolix can be increased when it is combined with Linagliptin.
Elbasvir
The metabolism of Elbasvir can be decreased when combined with Linagliptin.
Eletriptan
The metabolism of Eletriptan can be decreased when combined with Linagliptin.
Elexacaftor
The serum concentration of Elexacaftor can be increased when it is combined with Linagliptin.
Emapalumab
The metabolism of Linagliptin can be increased when combined with Emapalumab.
Enalapril
The risk or severity of angioedema can be increased when Linagliptin is combined with Enalapril.
Enalapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalapril.
Enalaprilat
The risk or severity of angioedema can be increased when Linagliptin is combined with Enalaprilat.
Enalaprilat
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Enalaprilat.
Encorafenib
The serum concentration of Encorafenib can be increased when it is combined with Linagliptin.
Enfortumab vedotin
The metabolism of Enfortumab vedotin can be decreased when combined with Linagliptin.
Enzalutamide
The serum concentration of Linagliptin can be decreased when it is combined with Enzalutamide.
Epcoritamab
The serum concentration of Linagliptin can be increased when it is combined with Epcoritamab.
Epinastine
The metabolism of Epinastine can be decreased when combined with Linagliptin.
Epinephrine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Epinephrine.
Epinephrine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epinephrine.
Eplerenone
The metabolism of Eplerenone can be decreased when combined with Linagliptin.
Eprosartan
The risk or severity of angioedema can be increased when Eprosartan is combined with Linagliptin.
Eravacycline
The metabolism of Eravacycline can be decreased when combined with Linagliptin.
Erdafitinib
The serum concentration of Linagliptin can be increased when it is combined with Erdafitinib.
Ertugliflozin
Ertugliflozin may increase the hypoglycemic activities of Linagliptin.
Ertugliflozin
Empagliflozin may increase the hypoglycemic activities of Ertugliflozin.
Erythromycin
The serum concentration of Linagliptin can be increased when it is combined with Erythromycin.
Escitalopram
The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Linagliptin.
Escitalopram
The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Empagliflozin.
Esketamine
The metabolism of Esketamine can be decreased when combined with Linagliptin.
Eslicarbazepine acetate
The metabolism of Linagliptin can be increased when combined with Eslicarbazepine acetate.
Esomeprazole
The metabolism of Esomeprazole can be decreased when combined with Linagliptin.
Estazolam
The metabolism of Estazolam can be decreased when combined with Linagliptin.
Esterified estrogens
The metabolism of Esterified estrogens can be decreased when combined with Linagliptin.
Estetrol
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Estetrol.
Estetrol
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estetrol.
Estradiol
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Estradiol.
Estradiol
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.
Estradiol acetate
The metabolism of Estradiol acetate can be decreased when combined with Linagliptin.
Estradiol cypionate
The metabolism of Estradiol cypionate can be decreased when combined with Linagliptin.
Estradiol valerate
The metabolism of Estradiol valerate can be decreased when combined with Linagliptin.
Estrone sulfate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Estrone sulfate.
Estrone sulfate
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estrone sulfate.
Eszopiclone
The metabolism of Eszopiclone can be decreased when combined with Linagliptin.
Etacrynic acid
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.
Etanercept
The metabolism of Linagliptin can be increased when combined with Etanercept.
Ethanol
The metabolism of Ethanol can be decreased when combined with Linagliptin.
Ethanol
Ethanol may increase the hypotensive activities of Empagliflozin.
Ethinylestradiol
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethinylestradiol.
Ethinylestradiol
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinylestradiol.
Ethosuximide
The metabolism of Ethosuximide can be decreased when combined with Linagliptin.
Ethosuximide
The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Empagliflozin.
Ethynodiol diacetate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ethynodiol diacetate.
Ethynodiol diacetate
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.
Etonogestrel
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Etonogestrel.
Etonogestrel
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.
Etrasimod
The serum concentration of Etrasimod can be increased when it is combined with Linagliptin.
Etravirine
The metabolism of Linagliptin can be increased when combined with Etravirine.
Everolimus
The metabolism of Everolimus can be decreased when combined with Linagliptin.
Everolimus
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.
Exemestane
The metabolism of Exemestane can be decreased when combined with Linagliptin.
Exenatide
The risk or severity of hypoglycemia can be increased when Exenatide is combined with Linagliptin.
Exenatide
Empagliflozin may increase the hypoglycemic activities of Exenatide.
Famotidine
The serum concentration of Linagliptin can be increased when it is combined with Famotidine.
Fedratinib
The serum concentration of Linagliptin can be increased when it is combined with Fedratinib.
Felbamate
The metabolism of Felbamate can be decreased when combined with Linagliptin.
Felodipine
The metabolism of Felodipine can be decreased when combined with Linagliptin.
Felodipine
The risk or severity of hypoglycemia can be increased when Felodipine is combined with Empagliflozin.
Fenofibrate
The metabolism of Fenofibrate can be decreased when combined with Linagliptin.
Fentanyl
The metabolism of Fentanyl can be decreased when combined with Linagliptin.
Fesoterodine
The metabolism of Fesoterodine can be decreased when combined with Linagliptin.
Fexinidazole
The metabolism of Fexinidazole can be decreased when combined with Linagliptin.
Fexofenadine
The serum concentration of Fexofenadine can be increased when it is combined with Linagliptin.
Finasteride
The metabolism of Finasteride can be decreased when combined with Linagliptin.
Finerenone
The serum concentration of Finerenone can be increased when it is combined with Linagliptin.
Fish oil
The metabolism of Fish oil can be decreased when combined with Linagliptin.
Fluconazole
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Fluconazole.
Fluconazole
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Fluconazole.
Fludrocortisone
The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Linagliptin.
Fludrocortisone
The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Empagliflozin.
Flunisolide
The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Linagliptin.
Flunisolide
The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Empagliflozin.
Fluocinolone acetonide
The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Linagliptin.
Fluocinolone acetonide
The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Empagliflozin.
Fluocinonide
The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Linagliptin.
Fluocinonide
The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Empagliflozin.
Fluorometholone
The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Linagliptin.
Fluorometholone
The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Empagliflozin.
Fluoxetine
The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Linagliptin.
Fluoxetine
The risk or severity of hypoglycemia can be increased when Fluoxetine is combined with Empagliflozin.
Flurandrenolide
The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Linagliptin.
Flurandrenolide
The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Empagliflozin.
Flurazepam
The metabolism of Flurazepam can be decreased when combined with Linagliptin.
Flutamide
The metabolism of Flutamide can be decreased when combined with Linagliptin.
Fluticasone furoate
The serum concentration of Fluticasone furoate can be increased when it is combined with Linagliptin.
Fluticasone furoate
The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Empagliflozin.
Fluticasone propionate
The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Linagliptin.
Fluticasone propionate
The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Empagliflozin.
Fluvastatin
The metabolism of Fluvastatin can be decreased when combined with Linagliptin.
Fluvoxamine
The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Linagliptin.
Fluvoxamine
The risk or severity of hypoglycemia can be increased when Fluvoxamine is combined with Empagliflozin.
Formoterol
The risk or severity of adverse effects can be increased when Linagliptin is combined with Formoterol.
Fosamprenavir
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Fosamprenavir.
Fosamprenavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fosamprenavir.
Fosaprepitant
The metabolism of Fosaprepitant can be decreased when combined with Linagliptin.
Fosinopril
The risk or severity of angioedema can be increased when Linagliptin is combined with Fosinopril.
Fosinopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Fosinopril.
Fosnetupitant
The metabolism of Fosnetupitant can be decreased when combined with Linagliptin.
Fosphenytoin
The metabolism of Linagliptin can be increased when combined with Fosphenytoin.
Fostamatinib
The metabolism of Fostamatinib can be decreased when combined with Linagliptin.
Fostemsavir
The metabolism of Fostemsavir can be decreased when combined with Linagliptin.
Fruquintinib
The metabolism of Fruquintinib can be decreased when combined with Linagliptin.
Furosemide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Furosemide.
Fusidic acid
The metabolism of Linagliptin can be decreased when combined with Fusidic acid.
Futibatinib
The serum concentration of Futibatinib can be increased when it is combined with Linagliptin.
Galantamine
The metabolism of Galantamine can be decreased when combined with Linagliptin.
Ganciclovir
The risk or severity of adverse effects can be increased when Linagliptin is combined with Ganciclovir.
Gatifloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Gatifloxacin.
Gatifloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gatifloxacin.
Gefitinib
The metabolism of Gefitinib can be decreased when combined with Linagliptin.
Gemfibrozil
The metabolism of Gemfibrozil can be decreased when combined with Linagliptin.
Gemifloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Gemifloxacin.
Gemifloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Gemifloxacin.
Genistein
The metabolism of Linagliptin can be increased when combined with Genistein.
Gepirone
The serum concentration of Gepirone can be increased when it is combined with Linagliptin.
Gepotidacin
The metabolism of Gepotidacin can be decreased when combined with Linagliptin.
Gestodene
The metabolism of Gestodene can be decreased when combined with Linagliptin.
Gilteritinib
The metabolism of Gilteritinib can be decreased when combined with Linagliptin.
Glasdegib
The metabolism of Glasdegib can be decreased when combined with Linagliptin.
Glecaprevir
The serum concentration of Glecaprevir can be increased when it is combined with Linagliptin.
Glimepiride
Linagliptin may increase the hypoglycemic activities of Glimepiride.
Glimepiride
Empagliflozin may increase the hypoglycemic activities of Glimepiride.
Glipizide
Linagliptin may increase the hypoglycemic activities of Glipizide.
Glipizide
Empagliflozin may increase the hypoglycemic activities of Glipizide.
Glofitamab
The serum concentration of Linagliptin can be increased when it is combined with Glofitamab.
Glyburide
Linagliptin may increase the hypoglycemic activities of Glyburide.
Glyburide
Empagliflozin may increase the hypoglycemic activities of Glyburide.
Glycerol phenylbutyrate
The metabolism of Linagliptin can be increased when combined with Glycerol phenylbutyrate.
Golimumab
The metabolism of Linagliptin can be increased when combined with Golimumab.
Goserelin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.
Goserelin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.
Granisetron
The metabolism of Granisetron can be decreased when combined with Linagliptin.
Grapefruit
The metabolism of Linagliptin can be decreased when combined with Grapefruit.
Grazoprevir
The metabolism of Grazoprevir can be decreased when combined with Linagliptin.
Griseofulvin
The metabolism of Linagliptin can be increased when combined with Griseofulvin.
Guanfacine
The metabolism of Guanfacine can be decreased when combined with Linagliptin.
Guanidine
The serum concentration of Linagliptin can be increased when it is combined with Guanidine.
Halcinonide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Linagliptin.
Halcinonide
The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Empagliflozin.
Haloperidol
The serum concentration of Haloperidol can be increased when it is combined with Linagliptin.
Haloperidol
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol.
Histamine
The serum concentration of Linagliptin can be increased when it is combined with Histamine.
Histrelin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Histrelin.
Histrelin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Histrelin.
Hydralazine
The metabolism of Linagliptin can be decreased when combined with Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydrochlorothiazide.
Hydrocodone
The metabolism of Hydrocodone can be decreased when combined with Linagliptin.
Hydrocortisone
The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Linagliptin.
Hydrocortisone
The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Empagliflozin.
Hydrocortisone acetate
The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Linagliptin.
Hydrocortisone acetate
The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Empagliflozin.
Hydrocortisone butyrate
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Linagliptin.
Hydrocortisone butyrate
The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Empagliflozin.
Hydrocortisone probutate
The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Linagliptin.
Hydrocortisone probutate
The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Empagliflozin.
Hydrocortisone succinate
The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Linagliptin.
Hydrocortisone succinate
The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Empagliflozin.
Hydrocortisone valerate
The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Linagliptin.
Hydrocortisone valerate
The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Empagliflozin.
Hydroflumethiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroflumethiazide.
Hydroxychloroquine
The therapeutic efficacy of Linagliptin can be increased when used in combination with Hydroxychloroquine.
Hydroxychloroquine
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Hydroxychloroquine.
Hydroxyprogesterone caproate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroxyprogesterone caproate.
Hydroxyprogesterone caproate
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.
Hydroxyzine
The metabolism of Hydroxyzine can be decreased when combined with Linagliptin.
Ibrexafungerp
The metabolism of Ibrexafungerp can be decreased when combined with Linagliptin.
Ibrutinib
The metabolism of Ibrutinib can be decreased when combined with Linagliptin.
Ibuprofen
The metabolism of Ibuprofen can be decreased when combined with Linagliptin.
Icatibant
The risk or severity of angioedema can be increased when Icatibant is combined with Linagliptin.
Iloperidone
The metabolism of Iloperidone can be decreased when combined with Linagliptin.
Iloperidone
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.
Imatinib
The metabolism of Imatinib can be decreased when combined with Linagliptin.
Imipramine
Imipramine may decrease the hypoglycemic activities of Empagliflozin.
Indapamide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.
Indinavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indinavir.
Indomethacin
The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Linagliptin.
Indomethacin
The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Empagliflozin.
Infliximab
The metabolism of Linagliptin can be increased when combined with Infliximab.
Insulin aspart
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin aspart.
Insulin aspart
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin aspart.
Insulin degludec
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin degludec.
Insulin degludec
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin degludec.
Insulin detemir
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin detemir.
Insulin detemir
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin detemir.
Insulin glargine
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin glargine.
Insulin glargine
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glargine.
Insulin glulisine
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin glulisine.
Insulin glulisine
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin glulisine.
Insulin human
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin human.
Insulin human
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin human.
Insulin lispro
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Insulin lispro.
Insulin lispro
The risk or severity of hypoglycemia can be increased when Empagliflozin is combined with Insulin lispro.
Ipecac
The metabolism of Ipecac can be decreased when combined with Linagliptin.
Irbesartan
The metabolism of Linagliptin can be decreased when combined with Irbesartan.
Isavuconazonium
The serum concentration of Linagliptin can be increased when it is combined with Isavuconazonium.
Isocarboxazid
Isocarboxazid may increase the orthostatic hypotensive activities of Empagliflozin.
Isoniazid
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Isoniazid.
Isoniazid
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Isoniazid.
Isotretinoin
The metabolism of Isotretinoin can be decreased when combined with Linagliptin.
Isradipine
The metabolism of Linagliptin can be decreased when combined with Isradipine.
Isradipine
The risk or severity of hypoglycemia can be increased when Isradipine is combined with Empagliflozin.
Istradefylline
The metabolism of Istradefylline can be decreased when combined with Linagliptin.
Ivacaftor
The metabolism of Ivacaftor can be decreased when combined with Linagliptin.
Ivermectin
The metabolism of Ivermectin can be decreased when combined with Linagliptin.
Ivosidenib
The metabolism of Ivosidenib can be decreased when combined with Linagliptin.
Ketamine
The metabolism of Ketamine can be decreased when combined with Linagliptin.
Labetalol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Labetalol.
Labetalol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Labetalol.
Lacosamide
The metabolism of Lacosamide can be decreased when combined with Linagliptin.
Lamivudine
The serum concentration of Lamivudine can be increased when it is combined with Linagliptin.
Lamotrigine
The serum concentration of Linagliptin can be increased when it is combined with Lamotrigine.
Lanreotide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lanreotide.
Lanreotide
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.
Lansoprazole
The metabolism of Lansoprazole can be decreased when combined with Linagliptin.
Lapatinib
The metabolism of Lapatinib can be decreased when combined with Linagliptin.
Larotrectinib
The metabolism of Larotrectinib can be decreased when combined with Linagliptin.
Lasmiditan
The serum concentration of Linagliptin can be increased when it is combined with Lasmiditan.
Lazertinib
The metabolism of Lazertinib can be decreased when combined with Linagliptin.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Linagliptin.
Lefamulin
Linagliptin may decrease the excretion rate of Lefamulin which could result in a higher serum level.
Lemborexant
The metabolism of Lemborexant can be decreased when combined with Linagliptin.
Lenacapavir
The metabolism of Lenacapavir can be decreased when combined with Linagliptin.
Lenvatinib
The serum concentration of Lenvatinib can be increased when it is combined with Linagliptin.
Letermovir
The metabolism of Linagliptin can be decreased when combined with Letermovir.
Letrozole
The metabolism of Letrozole can be decreased when combined with Linagliptin.
Leuprolide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.
Leuprolide
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.
Levamlodipine
The serum concentration of Levamlodipine can be increased when it is combined with Linagliptin.
Levamlodipine
The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Empagliflozin.
Levocetirizine
The metabolism of Levocetirizine can be decreased when combined with Linagliptin.
Levofloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Levofloxacin.
Levofloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Levofloxacin.
Levomenthol
The metabolism of Levomenthol can be decreased when combined with Linagliptin.
Levomilnacipran
The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Linagliptin.
Levomilnacipran
The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Empagliflozin.
Levonorgestrel
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Levonorgestrel.
Levonorgestrel
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levonorgestrel.
Lidocaine
The metabolism of Lidocaine can be decreased when combined with Linagliptin.
Linezolid
Linezolid may increase the orthostatic hypotensive activities of Empagliflozin.
Liothyronine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Liothyronine.
Liothyronine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Liothyronine.
Lipoic acid
The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Linagliptin.
Lipoic acid
The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Empagliflozin.
Liraglutide
The risk or severity of hypoglycemia can be increased when Liraglutide is combined with Linagliptin.
Liraglutide
Empagliflozin may increase the hypoglycemic activities of Liraglutide.
Lisinopril
The risk or severity of angioedema can be increased when Linagliptin is combined with Lisinopril.
Lisinopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Lisinopril.
Lixisenatide
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Lixisenatide.
Lixisenatide
Empagliflozin may increase the hypoglycemic activities of Lixisenatide.
Lomefloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Lomefloxacin.
Lomefloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Lomefloxacin.
Lonapegsomatropin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lonapegsomatropin.
Lonapegsomatropin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lonapegsomatropin.
Loncastuximab tesirine
The serum concentration of Loncastuximab tesirine can be increased when it is combined with Linagliptin.
Lopinavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.
Loratadine
The metabolism of Loratadine can be decreased when combined with Linagliptin.
Lorlatinib
The serum concentration of Linagliptin can be decreased when it is combined with Lorlatinib.
Losartan
The metabolism of Losartan can be decreased when combined with Linagliptin.
Lovastatin
The metabolism of Lovastatin can be decreased when combined with Linagliptin.
Loxapine
The serum concentration of Linagliptin can be increased when it is combined with Loxapine.
Lumacaftor
The serum concentration of Linagliptin can be decreased when it is combined with Lumacaftor.
Lumateperone
The serum concentration of Lumateperone can be increased when it is combined with Linagliptin.
Lumefantrine
The metabolism of Lumefantrine can be decreased when combined with Linagliptin.
Lurasidone
The metabolism of Lurasidone can be decreased when combined with Linagliptin.
Lurasidone
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.
Lurbinectedin
The serum concentration of Lurbinectedin can be increased when it is combined with Linagliptin.
Lusutrombopag
The serum concentration of Lusutrombopag can be increased when it is combined with Linagliptin.
Macimorelin
The metabolism of Macimorelin can be decreased when combined with Linagliptin.
Macitentan
The metabolism of Macitentan can be decreased when combined with Linagliptin.
Magnesium sulfate
The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Linagliptin.
Magnesium sulfate
The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Empagliflozin.
Mannitol
The serum concentration of Mannitol can be increased when it is combined with Linagliptin.
Maraviroc
The metabolism of Maraviroc can be decreased when combined with Linagliptin.
Maribavir
The metabolism of Maribavir can be decreased when combined with Linagliptin.
Mavacamten
The serum concentration of Mavacamten can be increased when it is combined with Linagliptin.
Mavorixafor
The metabolism of Mavorixafor can be decreased when combined with Linagliptin.
Mecasermin
The risk or severity of hypoglycemia can be increased when Mecasermin is combined with Linagliptin.
Mecasermin
Empagliflozin may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Medroxyprogesterone acetate.
Medroxyprogesterone acetate
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
Medrysone
The risk or severity of hyperglycemia can be increased when Medrysone is combined with Linagliptin.
Medrysone
The risk or severity of hyperglycemia can be increased when Medrysone is combined with Empagliflozin.
Mefloquine
The metabolism of Mefloquine can be decreased when combined with Linagliptin.
Megestrol acetate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Megestrol acetate.
Megestrol acetate
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Megestrol acetate.
Meloxicam
The metabolism of Meloxicam can be decreased when combined with Linagliptin.
Memantine
The serum concentration of Memantine can be increased when it is combined with Linagliptin.
Meperidine
The metabolism of Meperidine can be decreased when combined with Linagliptin.
Mesalazine
Mesalazine may increase the hypoglycemic activities of Linagliptin.
Mesalazine
Mesalazine may increase the hypoglycemic activities of Empagliflozin.
Methadone
The metabolism of Methadone can be decreased when combined with Linagliptin.
Methohexital
Methohexital may increase the hypotensive activities of Empagliflozin.
Methsuximide
The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Linagliptin.
Methsuximide
The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Empagliflozin.
Methyl salicylate
Methyl salicylate may increase the hypoglycemic activities of Linagliptin.
Methyl salicylate
Methyl salicylate may increase the hypoglycemic activities of Empagliflozin.
Methylene blue
The serum concentration of Methylene blue can be increased when it is combined with Linagliptin.
Methylene blue
Methylene blue may increase the orthostatic hypotensive activities of Empagliflozin.
Methylergometrine
The metabolism of Methylergometrine can be decreased when combined with Linagliptin.
Methylprednisolone
The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Linagliptin.
Methylprednisolone
The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Empagliflozin.
Methylprednisolone hemisuccinate
The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Linagliptin.
Methylprednisolone hemisuccinate
The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Empagliflozin.
Methyltestosterone
The metabolism of Methyltestosterone can be decreased when combined with Linagliptin.
Metoclopramide
The metabolism of Metoclopramide can be decreased when combined with Linagliptin.
Metolazone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone.
Metoprolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Metoprolol.
Metoprolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Metoprolol.
Metronidazole
The metabolism of Linagliptin can be decreased when combined with Metronidazole.
Metyrapone
The metabolism of Linagliptin can be increased when combined with Metyrapone.
Mexiletine
The metabolism of Mexiletine can be decreased when combined with Linagliptin.
Miconazole
The metabolism of Linagliptin can be decreased when combined with Miconazole.
Midazolam
The serum concentration of Midazolam can be increased when it is combined with Linagliptin.
Mifepristone
The serum concentration of Linagliptin can be decreased when it is combined with Mifepristone.
Mifepristone
Empagliflozin may increase the hypoglycemic activities of Mifepristone.
Miglitol
The risk or severity of hypoglycemia can be increased when Miglitol is combined with Linagliptin.
Miglitol
Empagliflozin may increase the hypoglycemic activities of Miglitol.
Milnacipran
The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Linagliptin.
Milnacipran
The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Empagliflozin.
Mirabegron
The metabolism of Mirabegron can be decreased when combined with Linagliptin.
Mirtazapine
The metabolism of Mirtazapine can be decreased when combined with Linagliptin.
Mitapivat
The metabolism of Mitapivat can be decreased when combined with Linagliptin.
Modafinil
The metabolism of Linagliptin can be increased when combined with Modafinil.
Moexipril
The risk or severity of angioedema can be increased when Linagliptin is combined with Moexipril.
Moexipril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Moexipril.
Mometasone furoate
The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Linagliptin.
Mometasone furoate
The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Empagliflozin.
Montelukast
The metabolism of Montelukast can be decreased when combined with Linagliptin.
Morphine
The metabolism of Morphine can be decreased when combined with Linagliptin.
Moxifloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Moxifloxacin.
Moxifloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.
Mycophenolate mofetil
The metabolism of Mycophenolate mofetil can be decreased when combined with Linagliptin.
Nabilone
The metabolism of Nabilone can be decreased when combined with Linagliptin.
Nadolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Nadolol.
Nadolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nadolol.
Nafcillin
The metabolism of Linagliptin can be increased when combined with Nafcillin.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Linagliptin.
Nateglinide
The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Linagliptin.
Nateglinide
Empagliflozin may increase the hypoglycemic activities of Nateglinide.
Nebivolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Nebivolol.
Nebivolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nebivolol.
Nefazodone
The risk or severity of hypoglycemia can be increased when Nefazodone is combined with Empagliflozin.
Nelfinavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.
Netupitant
The metabolism of Netupitant can be decreased when combined with Linagliptin.
Nevirapine
The metabolism of Nevirapine can be decreased when combined with Linagliptin.
Niacin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Niacin.
Niacin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Niacin.
Nicardipine
The metabolism of Linagliptin can be decreased when combined with Nicardipine.
Nicardipine
The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Empagliflozin.
Nicotine
The serum concentration of Linagliptin can be increased when it is combined with Nicotine.
Nifedipine
The metabolism of Nifedipine can be decreased when combined with Linagliptin.
Nifedipine
The risk or severity of hypoglycemia can be increased when Nifedipine is combined with Empagliflozin.
Nilotinib
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.
Nimodipine
The metabolism of Nimodipine can be decreased when combined with Linagliptin.
Nimodipine
The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Empagliflozin.
Nintedanib
The metabolism of Nintedanib can be decreased when combined with Linagliptin.
Nirmatrelvir
The metabolism of Nirmatrelvir can be decreased when combined with Linagliptin.
Nirogacestat
The serum concentration of Nirogacestat can be increased when it is combined with Linagliptin.
Nisoldipine
The metabolism of Nisoldipine can be decreased when combined with Linagliptin.
Nisoldipine
The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Empagliflozin.
Norelgestromin
The metabolism of Norelgestromin can be decreased when combined with Linagliptin.
Norepinephrine
The serum concentration of Linagliptin can be increased when it is combined with Norepinephrine.
Norethisterone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Norethisterone.
Norethisterone
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norethisterone.
Norgestimate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Norgestimate.
Norgestimate
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norgestimate.
Norgestrel
The metabolism of Norgestrel can be decreased when combined with Linagliptin.
Nortriptyline
Nortriptyline may decrease the hypoglycemic activities of Empagliflozin.
Octreotide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.
Octreotide
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.
Ofloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Ofloxacin.
Ofloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Ofloxacin.
Olanzapine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Olanzapine.
Olanzapine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.
Olaparib
The metabolism of Olaparib can be decreased when combined with Linagliptin.
Oliceridine
The serum concentration of Oliceridine can be increased when it is combined with Linagliptin.
Olsalazine
Olsalazine may increase the hypoglycemic activities of Linagliptin.
Olsalazine
Olsalazine may increase the hypoglycemic activities of Empagliflozin.
Olutasidenib
The metabolism of Olutasidenib can be decreased when combined with Linagliptin.
Omadacycline
The serum concentration of Omadacycline can be increased when it is combined with Linagliptin.
Ombitasvir
The serum concentration of Ombitasvir can be increased when it is combined with Linagliptin.
Ondansetron
The metabolism of Ondansetron can be decreased when combined with Linagliptin.
Opium
The metabolism of Opium can be decreased when combined with Linagliptin.
Oritavancin
The metabolism of Linagliptin can be increased when combined with Oritavancin.
Orphenadrine
The metabolism of Orphenadrine can be decreased when combined with Linagliptin.
Osilodrostat
The metabolism of Osilodrostat can be decreased when combined with Linagliptin.
Ospemifene
The metabolism of Ospemifene can be decreased when combined with Linagliptin.
Oxcarbazepine
The metabolism of Linagliptin can be increased when combined with Oxcarbazepine.
Oxybutynin
The metabolism of Oxybutynin can be decreased when combined with Linagliptin.
Oxycodone
The metabolism of Oxycodone can be decreased when combined with Linagliptin.
Oxymorphone
The metabolism of Oxymorphone can be decreased when combined with Linagliptin.
Paliperidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Paliperidone.
Paliperidone
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.
Palonosetron
The metabolism of Palonosetron can be decreased when combined with Linagliptin.
Palovarotene
The serum concentration of Palovarotene can be increased when it is combined with Linagliptin.
Pancuronium
The risk or severity of adverse effects can be increased when Linagliptin is combined with Pancuronium.
Pantoprazole
The metabolism of Pantoprazole can be decreased when combined with Linagliptin.
Parecoxib
The metabolism of Parecoxib can be decreased when combined with Linagliptin.
Paricalcitol
The metabolism of Paricalcitol can be decreased when combined with Linagliptin.
Paritaprevir
The metabolism of Paritaprevir can be decreased when combined with Linagliptin.
Paroxetine
The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Linagliptin.
Paroxetine
The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Empagliflozin.
Pasireotide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pasireotide.
Pasireotide
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Linagliptin.
Pegvisomant
The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Linagliptin.
Pegvisomant
The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Empagliflozin.
Pemigatinib
The metabolism of Pemigatinib can be decreased when combined with Linagliptin.
Pentamidine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pentamidine.
Pentamidine
Empagliflozin may increase the hypoglycemic activities of Pentamidine.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Empagliflozin.
Perampanel
The metabolism of Perampanel can be decreased when combined with Linagliptin.
Perindopril
The risk or severity of angioedema can be increased when Linagliptin is combined with Perindopril.
Perindopril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Perindopril.
Phenelzine
Phenelzine may increase the orthostatic hypotensive activities of Empagliflozin.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Empagliflozin.
Phenoxybenzamine
The serum concentration of Linagliptin can be increased when it is combined with Phenoxybenzamine.
Phentermine
The therapeutic efficacy of Linagliptin can be increased when used in combination with Phentermine.
Phentermine
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Phentermine.
Phenytoin
The metabolism of Linagliptin can be increased when combined with Phenytoin.
Phenytoin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Phenytoin.
Pibrentasvir
The serum concentration of Pibrentasvir can be increased when it is combined with Linagliptin.
Pinaverium
The metabolism of Pinaverium can be decreased when combined with Linagliptin.
Pinaverium
The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Empagliflozin.
Pindolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Pindolol.
Pindolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Pindolol.
Pioglitazone
The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Linagliptin.
Pioglitazone
Empagliflozin may increase the hypoglycemic activities of Pioglitazone.
Piperine
The serum concentration of Linagliptin can be increased when it is combined with Piperine.
Pirtobrutinib
The metabolism of Pirtobrutinib can be decreased when combined with Linagliptin.
Pitolisant
The serum concentration of Linagliptin can be decreased when it is combined with Pitolisant.
Polatuzumab vedotin
The metabolism of Polatuzumab vedotin can be decreased when combined with Linagliptin.
Polythiazide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Polythiazide.
Ponesimod
The metabolism of Ponesimod can be decreased when combined with Linagliptin.
Pralsetinib
The serum concentration of Pralsetinib can be increased when it is combined with Linagliptin.
Pramipexole
The serum concentration of Pramipexole can be increased when it is combined with Linagliptin.
Pramlintide
The risk or severity of hypoglycemia can be increased when Pramlintide is combined with Linagliptin.
Pramlintide
Empagliflozin may increase the hypoglycemic activities of Pramlintide.
Prasterone
The metabolism of Prasterone can be decreased when combined with Linagliptin.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Linagliptin.
Praziquantel
The metabolism of Praziquantel can be decreased when combined with Linagliptin.
Prazosin
The serum concentration of Prazosin can be increased when it is combined with Linagliptin.
Prednicarbate
The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Linagliptin.
Prednicarbate
The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Empagliflozin.
Prednisolone
The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Linagliptin.
Prednisolone
The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Empagliflozin.
Prednisolone acetate
The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Linagliptin.
Prednisolone acetate
The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Empagliflozin.
Prednisolone phosphate
The serum concentration of Linagliptin can be decreased when it is combined with Prednisolone phosphate.
Prednisolone phosphate
The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Empagliflozin.
Prednisone
The risk or severity of hyperglycemia can be increased when Prednisone is combined with Linagliptin.
Prednisone
The risk or severity of hyperglycemia can be increased when Prednisone is combined with Empagliflozin.
Pregabalin
The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Linagliptin.
Pregabalin
The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Empagliflozin.
Pregnenolone
The metabolism of Pregnenolone can be decreased when combined with Linagliptin.
Primaquine
The metabolism of Linagliptin can be decreased when combined with Primaquine.
Primidone
Primidone may increase the hypotensive activities of Empagliflozin.
Probenecid
The serum concentration of Linagliptin can be increased when it is combined with Probenecid.
Procaine
Procaine may increase the orthostatic hypotensive activities of Empagliflozin.
Procarbazine
Procarbazine may increase the orthostatic hypotensive activities of Empagliflozin.
Prochlorperazine
The metabolism of Prochlorperazine can be decreased when combined with Linagliptin.
Progesterone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Progesterone.
Progesterone
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.
Propafenone
The therapeutic efficacy of Linagliptin can be increased when used in combination with Propafenone.
Propafenone
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propafenone.
Propranolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Propranolol.
Propranolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Propranolol.
Protriptyline
Protriptyline may decrease the hypoglycemic activities of Linagliptin.
Protriptyline
Protriptyline may decrease the hypoglycemic activities of Empagliflozin.
Prucalopride
The serum concentration of Prucalopride can be increased when it is combined with Linagliptin.
Pseudoephedrine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pseudoephedrine.
Pseudoephedrine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pseudoephedrine.
Quazepam
The metabolism of Quazepam can be decreased when combined with Linagliptin.
Quetiapine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.
Quetiapine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quetiapine.
Quinapril
The risk or severity of angioedema can be increased when Linagliptin is combined with Quinapril.
Quinapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Quinapril.
Quinine
The risk or severity of hypoglycemia can be increased when Quinine is combined with Linagliptin.
Quinine
Empagliflozin may increase the hypoglycemic activities of Quinine.
Quizartinib
The metabolism of Quizartinib can be decreased when combined with Linagliptin.
Raloxifene
The metabolism of Linagliptin can be decreased when combined with Raloxifene.
Ramelteon
The metabolism of Ramelteon can be decreased when combined with Linagliptin.
Ramipril
The risk or severity of angioedema can be increased when Linagliptin is combined with Ramipril.
Ramipril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Ramipril.
Ranitidine
The serum concentration of Linagliptin can be increased when it is combined with Ranitidine.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Linagliptin.
Rasagiline
Rasagiline may increase the orthostatic hypotensive activities of Empagliflozin.
Relugolix
The serum concentration of Relugolix can be increased when it is combined with Linagliptin.
Remdesivir
The metabolism of Remdesivir can be decreased when combined with Linagliptin.
Repaglinide
The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Linagliptin.
Repaglinide
Empagliflozin may increase the hypoglycemic activities of Repaglinide.
Repotrectinib
The serum concentration of Repotrectinib can be increased when it is combined with Linagliptin.
Reserpine
The serum concentration of Linagliptin can be increased when it is combined with Reserpine.
Retapamulin
The metabolism of Retapamulin can be decreased when combined with Linagliptin.
Revefenacin
The serum concentration of Revefenacin can be increased when it is combined with Linagliptin.
Revumenib
The metabolism of Revumenib can be decreased when combined with Linagliptin.
Rifabutin
The metabolism of Rifabutin can be decreased when combined with Linagliptin.
Rifampin
The serum concentration of Linagliptin can be decreased when it is combined with Rifampicin.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Linagliptin.
Rilonacept
The metabolism of Linagliptin can be increased when combined with Rilonacept.
Rilpivirine
The metabolism of Rilpivirine can be decreased when combined with Linagliptin.
Rilzabrutinib
The metabolism of Rilzabrutinib can be decreased when combined with Linagliptin.
Riociguat
The metabolism of Riociguat can be decreased when combined with Linagliptin.
Ripretinib
The metabolism of Ripretinib can be decreased when combined with Linagliptin.
Risperidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Risperidone.
Ritlecitinib
The serum concentration of Linagliptin can be increased when it is combined with Ritlecitinib.
Ritonavir
The serum concentration of Linagliptin can be increased when it is combined with Ritonavir.
Ritonavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.
Rivaroxaban
The metabolism of Rivaroxaban can be decreased when combined with Linagliptin.
Rocuronium
The risk or severity of adverse effects can be increased when Linagliptin is combined with Rocuronium.
Roflumilast
The serum concentration of Roflumilast can be increased when it is combined with Linagliptin.
Rolapitant
The metabolism of Rolapitant can be decreased when combined with Linagliptin.
Rosiglitazone
The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Linagliptin.
Rosiglitazone
Empagliflozin may increase the hypoglycemic activities of Rosiglitazone.
Rosuvastatin
The metabolism of Rosuvastatin can be decreased when combined with Linagliptin.
Rotigotine
The metabolism of Rotigotine can be decreased when combined with Linagliptin.
Rucaparib
The metabolism of Rucaparib can be decreased when combined with Linagliptin.
Rufinamide
The metabolism of Linagliptin can be increased when combined with Rufinamide.
Sacubitril
The risk or severity of angioedema can be increased when Linagliptin is combined with Sacubitril.
Safinamide
The metabolism of Safinamide can be decreased when combined with Linagliptin.
Safinamide
Safinamide may increase the orthostatic hypotensive activities of Empagliflozin.
Salicylic acid
Salicylic acid may increase the hypoglycemic activities of Linagliptin.
Salicylic acid
Salicylic acid may increase the hypoglycemic activities of Empagliflozin.
Salmeterol
The metabolism of Salmeterol can be decreased when combined with Linagliptin.
Samidorphan
The metabolism of Samidorphan can be decreased when combined with Linagliptin.
Sapropterin
The serum concentration of Linagliptin can be increased when it is combined with Sapropterin.
Saquinavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.
Sarecycline
The serum concentration of Linagliptin can be increased when it is combined with Sarecycline.
Sarilumab
The metabolism of Linagliptin can be increased when combined with Sarilumab.
Satralizumab
The serum concentration of Linagliptin can be decreased when it is combined with Satralizumab.
Saxagliptin
The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Linagliptin.
Saxagliptin
Empagliflozin may increase the hypoglycemic activities of Saxagliptin.
Scopolamine
The metabolism of Scopolamine can be decreased when combined with Linagliptin.
Sebetralstat
The metabolism of Sebetralstat can be decreased when combined with Linagliptin.
Secobarbital
The metabolism of Linagliptin can be increased when combined with Secobarbital.
Secobarbital
Secobarbital may increase the hypotensive activities of Empagliflozin.
Secukinumab
The metabolism of Linagliptin can be increased when combined with Secukinumab.
Selegiline
The metabolism of Selegiline can be decreased when combined with Linagliptin.
Selegiline
Selegiline may increase the orthostatic hypotensive activities of Empagliflozin.
Selexipag
The metabolism of Selexipag can be decreased when combined with Linagliptin.
Selinexor
The metabolism of Selinexor can be decreased when combined with Linagliptin.
Selpercatinib
The metabolism of Selpercatinib can be decreased when combined with Linagliptin.
Semaglutide
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Semaglutide.
Semaglutide
Empagliflozin may increase the hypoglycemic activities of Semaglutide.
Sertraline
The risk or severity of hypoglycemia can be increased when Sertraline is combined with Linagliptin.
Sertraline
The risk or severity of hypoglycemia can be increased when Sertraline is combined with Empagliflozin.
Sildenafil
The metabolism of Sildenafil can be decreased when combined with Linagliptin.
Siltuximab
The metabolism of Linagliptin can be increased when combined with Siltuximab.
Simvastatin
The metabolism of Simvastatin can be decreased when combined with Linagliptin.
Sirolimus
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.
Sitagliptin
The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Linagliptin.
Sitagliptin
Empagliflozin may increase the hypoglycemic activities of Sitagliptin.
Sodium ferric gluconate complex
The risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Empagliflozin.
Sofosbuvir
The serum concentration of Sofosbuvir can be increased when it is combined with Linagliptin.
Solifenacin
The metabolism of Solifenacin can be decreased when combined with Linagliptin.
Solriamfetol
The serum concentration of Solriamfetol can be increased when it is combined with Linagliptin.
Somapacitan
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Somapacitan.
Somapacitan
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somapacitan.
Somatotropin
Somatotropin may decrease the hypoglycemic activities of Linagliptin.
Somatotropin
Somatotropin may decrease the hypoglycemic activities of Empagliflozin.
Somatrogon
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Somatrogon.
Somatrogon
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Somatrogon.
Sonidegib
The metabolism of Sonidegib can be decreased when combined with Linagliptin.
Sotagliflozin
The serum concentration of Linagliptin can be increased when it is combined with Sotagliflozin.
Sotagliflozin
Empagliflozin may increase the hypoglycemic activities of Sotagliflozin.
Sotalol
The risk or severity of hypoglycemia can be increased when Sotalol is combined with Linagliptin.
Sotalol
The risk or severity of hypoglycemia can be increased when Sotalol is combined with Empagliflozin.
Sotorasib
The serum concentration of Linagliptin can be decreased when it is combined with Sotorasib.
Sparsentan
The metabolism of Sparsentan can be decreased when combined with Linagliptin.
Stiripentol
The metabolism of Linagliptin can be decreased when combined with Stiripentol.
Sufentanil
The metabolism of Sufentanil can be decreased when combined with Linagliptin.
Sulfadiazine
The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Linagliptin.
Sulfadiazine
Empagliflozin may increase the hypoglycemic activities of Sulfadiazine.
Sulfamethoxazole
The risk or severity of hypoglycemia can be increased when Sulfamethoxazole is combined with Linagliptin.
Sulfamethoxazole
Empagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.
Sulfasalazine
Sulfasalazine may increase the hypoglycemic activities of Linagliptin.
Sulfasalazine
Sulfasalazine may increase the hypoglycemic activities of Empagliflozin.
Sunitinib
Empagliflozin may increase the hypoglycemic activities of Sunitinib.
Suvorexant
The metabolism of Suvorexant can be decreased when combined with Linagliptin.
Suzetrigine
The metabolism of Suzetrigine can be decreased when combined with Linagliptin.
Synthetic Conjugated Estrogens, A
The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Linagliptin.
Synthetic Conjugated Estrogens, B
The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Linagliptin.
Tacrolimus
The serum concentration of Tacrolimus can be increased when it is combined with Linagliptin.
Tacrolimus
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.
Tadalafil
The metabolism of Tadalafil can be decreased when combined with Linagliptin.
Tafenoquine
The serum concentration of Linagliptin can be increased when it is combined with Tafenoquine.
Taletrectinib
The metabolism of Taletrectinib can be decreased when combined with Linagliptin.
Tamsulosin
The metabolism of Tamsulosin can be decreased when combined with Linagliptin.
Tasimelteon
The metabolism of Tasimelteon can be decreased when combined with Linagliptin.
Tazemetostat
The metabolism of Tazemetostat can be decreased when combined with Linagliptin.
Technetium Tc-99m sestamibi
The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Linagliptin.
Tecovirimat
The metabolism of Linagliptin can be increased when combined with Tecovirimat.
Tegaserod
The serum concentration of Tegaserod can be increased when it is combined with Linagliptin.
Telmisartan
The risk or severity of angioedema can be increased when Telmisartan is combined with Linagliptin.
Telotristat ethyl
The serum concentration of Linagliptin can be decreased when it is combined with Telotristat ethyl.
Temsirolimus
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.
Tenecteplase
The risk or severity of angioedema can be increased when Tenecteplase is combined with Linagliptin.
Tenofovir alafenamide
The serum concentration of Tenofovir alafenamide can be increased when it is combined with Linagliptin.
Tenofovir disoproxil
The serum concentration of Tenofovir disoproxil can be increased when it is combined with Linagliptin.
Teprotumumab
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Teprotumumab.
Teprotumumab
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Teprotumumab.
Terbinafine
The metabolism of Terbinafine can be decreased when combined with Linagliptin.
Testosterone
The metabolism of Testosterone can be decreased when combined with Linagliptin.
Testosterone cypionate
The metabolism of Testosterone cypionate can be decreased when combined with Linagliptin.
Testosterone enanthate
The metabolism of Testosterone enanthate can be decreased when combined with Linagliptin.
Testosterone propionate
The metabolism of Testosterone propionate can be decreased when combined with Linagliptin.
Tetracycline
The metabolism of Tetracycline can be decreased when combined with Linagliptin.
Tezacaftor
The metabolism of Tezacaftor can be decreased when combined with Linagliptin.
Thalidomide
The metabolism of Thalidomide can be decreased when combined with Linagliptin.
Thiamine
The serum concentration of Linagliptin can be increased when it is combined with Thiamine.
Thyroid, porcine
Thyroid, porcine may decrease the hypoglycemic activities of Linagliptin.
Thyroid, porcine
Thyroid, porcine may decrease the hypoglycemic activities of Empagliflozin.
Thyrotropin alfa
Thyrotropin alfa may decrease the hypoglycemic activities of Linagliptin.
Thyrotropin alfa
Thyrotropin alfa may decrease the hypoglycemic activities of Empagliflozin.
Tiagabine
The metabolism of Tiagabine can be decreased when combined with Linagliptin.
Ticagrelor
The metabolism of Ticagrelor can be decreased when combined with Linagliptin.
Timolol
The therapeutic efficacy of Linagliptin can be increased when used in combination with Timolol.
Timolol
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Timolol.
Tinidazole
The metabolism of Tinidazole can be decreased when combined with Linagliptin.
Tiotropium
The metabolism of Tiotropium can be decreased when combined with Linagliptin.
Tipranavir
The serum concentration of Linagliptin can be decreased when it is combined with Tipranavir.
Tipranavir
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.
Tirzepatide
The risk or severity of hypoglycemia can be increased when Linagliptin is combined with Tirzepatide.
Tirzepatide
Empagliflozin may increase the hypoglycemic activities of Tirzepatide.
Tisotumab vedotin
The metabolism of Tisotumab vedotin can be decreased when combined with Linagliptin.
Tivozanib
The serum concentration of Tivozanib can be increased when it is combined with Linagliptin.
Tixocortol
The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Linagliptin.
Tixocortol
The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Empagliflozin.
Tocilizumab
The metabolism of Linagliptin can be increased when combined with Tocilizumab.
Tocofersolan
The metabolism of Tocofersolan can be decreased when combined with Linagliptin.
Tocopherol
The metabolism of Tocopherol can be decreased when combined with Linagliptin.
Tofacitinib
The metabolism of Tofacitinib can be decreased when combined with Linagliptin.
Tolazamide
Linagliptin may increase the hypoglycemic activities of Tolazamide.
Tolazamide
Empagliflozin may increase the hypoglycemic activities of Tolazamide.
Tolterodine
The metabolism of Tolterodine can be decreased when combined with Linagliptin.
Topiramate
The metabolism of Linagliptin can be increased when combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Linagliptin.
Torasemide
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.
Toremifene
The metabolism of Toremifene can be decreased when combined with Linagliptin.
Tovorafenib
The metabolism of Linagliptin can be increased when combined with Tovorafenib.
Tramadol
The metabolism of Tramadol can be decreased when combined with Linagliptin.
Trandolapril
The risk or severity of angioedema can be increased when Linagliptin is combined with Trandolapril.
Trandolapril
The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Trandolapril.
Tranylcypromine
Tranylcypromine may increase the orthostatic hypotensive activities of Empagliflozin.
Trazodone
The serum concentration of Linagliptin can be decreased when it is combined with Trazodone.
Treosulfan
The metabolism of Linagliptin can be decreased when combined with Treosulfan.
Tretinoin
The metabolism of Tretinoin can be decreased when combined with Linagliptin.
Triamcinolone
The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Linagliptin.
Triamcinolone
The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Empagliflozin.
Triazolam
The metabolism of Triazolam can be decreased when combined with Linagliptin.
Triclabendazole
The metabolism of Triclabendazole can be decreased when combined with Linagliptin.
Trilaciclib
The serum concentration of Trilaciclib can be increased when it is combined with Linagliptin.
Trimethoprim
The metabolism of Trimethoprim can be decreased when combined with Linagliptin.
Trimipramine
Trimipramine may decrease the hypoglycemic activities of Empagliflozin.
Triptorelin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Triptorelin.
Triptorelin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.
Trolamine salicylate
Trolamine salicylate may increase the hypoglycemic activities of Linagliptin.
Trolamine salicylate
Trolamine salicylate may increase the hypoglycemic activities of Empagliflozin.
Trovafloxacin
The therapeutic efficacy of Linagliptin can be increased when used in combination with Trovafloxacin.
Trovafloxacin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Trovafloxacin.
Tucatinib
Tucatinib may decrease the excretion rate of Linagliptin which could result in a higher serum level.
Ubidecarenone
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Linagliptin.
Ubidecarenone
The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Empagliflozin.
Ubrogepant
The serum concentration of Ubrogepant can be increased when it is combined with Linagliptin.
Ulipristal
The metabolism of Ulipristal can be decreased when combined with Linagliptin.
Ulobetasol
The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Linagliptin.
Ulobetasol
The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Empagliflozin.
Umeclidinium
The serum concentration of Umeclidinium can be increased when it is combined with Linagliptin.
Upadacitinib
The metabolism of Upadacitinib can be decreased when combined with Linagliptin.
Urokinase
The risk or severity of angioedema can be increased when Urokinase is combined with Linagliptin.
Valbenazine
The metabolism of Valbenazine can be decreased when combined with Linagliptin.
Valdecoxib
The metabolism of Valdecoxib can be decreased when combined with Linagliptin.
Valproic acid
The metabolism of Linagliptin can be decreased when combined with Valproic acid.
Valsartan
The risk or severity of angioedema can be increased when Valsartan is combined with Linagliptin.
Vamorolone
The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Linagliptin.
Vamorolone
The risk or severity of hyperglycemia can be increased when Vamorolone is combined with Empagliflozin.
Vardenafil
The metabolism of Vardenafil can be decreased when combined with Linagliptin.
Velpatasvir
The metabolism of Velpatasvir can be decreased when combined with Linagliptin.
Vemurafenib
The serum concentration of Linagliptin can be increased when it is combined with Vemurafenib.
Venlafaxine
The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Linagliptin.
Venlafaxine
The risk or severity of hypoglycemia can be increased when Venlafaxine is combined with Empagliflozin.
Verapamil
The metabolism of Linagliptin can be decreased when combined with Verapamil.
Verapamil
The risk or severity of hypoglycemia can be increased when Verapamil is combined with Empagliflozin.
Vilanterol
The metabolism of Vilanterol can be decreased when combined with Linagliptin.
Vilazodone
The metabolism of Vilazodone can be decreased when combined with Linagliptin.
Vimseltinib
The serum concentration of Linagliptin can be increased when it is combined with Vimseltinib.
Vincristine
The excretion of Vincristine can be decreased when combined with Linagliptin.
Vitamin D
The metabolism of Vitamin D can be decreased when combined with Linagliptin.
Vitamin E
The metabolism of Vitamin E can be decreased when combined with Linagliptin.
Voclosporin
The metabolism of Voclosporin can be decreased when combined with Linagliptin.
Vonoprazan
The metabolism of Vonoprazan can be decreased when combined with Linagliptin.
Vorapaxar
The metabolism of Vorapaxar can be decreased when combined with Linagliptin.
Vorasidenib
The metabolism of Linagliptin can be increased when combined with Vorasidenib.
Vorinostat
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Vorinostat.
Vorinostat
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.
Vortioxetine
The metabolism of Vortioxetine can be decreased when combined with Linagliptin.
Voxelotor
The serum concentration of Voxelotor can be increased when it is combined with Linagliptin.
Voxilaprevir
The metabolism of Voxilaprevir can be decreased when combined with Linagliptin.
Warfarin
The serum concentration of Warfarin can be increased when it is combined with Linagliptin.
Xylometazoline
The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Linagliptin.
Xylometazoline
The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Empagliflozin.
Zafirlukast
The metabolism of Linagliptin can be decreased when combined with Zafirlukast.
Zaleplon
The metabolism of Zaleplon can be decreased when combined with Linagliptin.
Zanubrutinib
The metabolism of Zanubrutinib can be decreased when combined with Linagliptin.
Ziconotide
The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Linagliptin.
Ziconotide
The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Empagliflozin.
Zidovudine
The metabolism of Zidovudine can be decreased when combined with Linagliptin.
Zileuton
The metabolism of Zileuton can be decreased when combined with Linagliptin.
Ziprasidone
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Ziprasidone.
Ziprasidone
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.
Zolpidem
The metabolism of Zolpidem can be decreased when combined with Linagliptin.
Zonisamide
The metabolism of Zonisamide can be decreased when combined with Linagliptin.
Zuranolone
The metabolism of Zuranolone can be decreased when combined with Linagliptin.
Abaloparatide
The risk or severity of adverse effects can be increased when Abaloparatide is combined with Empagliflozin.
Acetazolamide
Empagliflozin may increase the diuretic activities of Acetazolamide.
Acetyl sulfisoxazole
The therapeutic efficacy of Linagliptin can be increased when used in combination with Acetyl sulfisoxazole.
Acetyl sulfisoxazole
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Acetyl sulfisoxazole.
Albuterol
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Albuterol.
Albuterol
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Albuterol.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.
Aliskiren
The risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.
Ambrisentan
Empagliflozin may increase the hypotensive activities of Ambrisentan.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Empagliflozin.
Amiloride
Empagliflozin may increase the diuretic activities of Amiloride.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Empagliflozin.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Empagliflozin.
Aprocitentan
Empagliflozin may increase the hypotensive activities of Aprocitentan.
Arimoclomol
The serum concentration of Linagliptin can be increased when it is combined with Arimoclomol.
Aripiprazole lauroxil
Aripiprazole lauroxil may increase the hypotensive activities of Empagliflozin.
Avanafil
The risk or severity of hypotension can be increased when Avanafil is combined with Empagliflozin.
Azilsartan medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.
Bendroflumethiazide
Empagliflozin may increase the diuretic activities of Bendroflumethiazide.
Bimatoprost
Empagliflozin may increase the hypotensive activities of Bimatoprost.
Bosentan
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Bosentan.
Bretylium
The risk or severity of adverse effects can be increased when Bretylium is combined with Empagliflozin.
Brinzolamide
Empagliflozin may increase the diuretic activities of Brinzolamide.
Bromotheophylline
Empagliflozin may increase the diuretic activities of Bromotheophylline.
Bumetanide
Empagliflozin may increase the diuretic activities of Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Empagliflozin.
Candesartan cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Empagliflozin.
Celecoxib
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Celecoxib.
Chlorothiazide
Empagliflozin may increase the diuretic activities of Chlorothiazide.
Chlorthalidone
Empagliflozin may increase the diuretic activities of Chlorthalidone.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Empagliflozin.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.
Conivaptan
Empagliflozin may increase the diuretic activities of Conivaptan.
Dalfopristin
The metabolism of Linagliptin can be decreased when combined with Dalfopristin.
Dasiglucagon
Empagliflozin may increase the hypotensive activities of Dasiglucagon.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Empagliflozin.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.
Diclofenamide
The therapeutic efficacy of Linagliptin can be increased when used in combination with Diclofenamide.
Diclofenamide
Empagliflozin may increase the diuretic activities of Diclofenamide.
Dinutuximab
The risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.
Dipyridamole
The risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.
Dorzolamide
Empagliflozin may increase the diuretic activities of Dorzolamide.
Doxazosin
The risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.
Drospirenone
Empagliflozin may increase the diuretic activities of Drospirenone.
Duloxetine
The risk or severity of orthostatic hypotension and syncope can be increased when Empagliflozin is combined with Duloxetine.
Ensartinib
The serum concentration of Ensartinib can be increased when it is combined with Linagliptin.
Eplerenone
Empagliflozin may increase the diuretic activities of Eplerenone.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Empagliflozin.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.
Etacrynic acid
Empagliflozin may increase the diuretic activities of Etacrynic acid.
Ethambutol
The metabolism of Linagliptin can be decreased when combined with Ethambutol.
Fedratinib
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Fedratinib.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Empagliflozin.
Finerenone
Empagliflozin may increase the diuretic activities of Finerenone.
Fluoxymesterone
Fluoxymesterone may increase the hypoglycemic activities of Linagliptin.
Fluoxymesterone
Fluoxymesterone may increase the hypoglycemic activities of Empagliflozin.
Fostamatinib
The risk or severity of hypotension can be increased when Fostamatinib is combined with Empagliflozin.
Furosemide
Empagliflozin may increase the diuretic activities of Furosemide.
Ginkgo biloba
The metabolism of Linagliptin can be decreased when combined with Ginkgo biloba.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.
Hydralazine
The risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.
Hydrochlorothiazide
Empagliflozin may increase the diuretic activities of Hydrochlorothiazide.
Hydroflumethiazide
Empagliflozin may increase the diuretic activities of Hydroflumethiazide.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Empagliflozin.
Indapamide
Empagliflozin may increase the diuretic activities of Indapamide.
Irbesartan
The risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.
Isocarboxazid
Isocarboxazid may increase the hypoglycemic activities of Linagliptin.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Empagliflozin.
Isosorbide
Empagliflozin may increase the diuretic activities of Isosorbide.
Isosorbide dinitrate
The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Empagliflozin.
Isosorbide mononitrate
The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Empagliflozin.
Isoxsuprine
The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Empagliflozin.
Ketotifen
The risk or severity of thrombocytopenia can be increased when Linagliptin is combined with Ketotifen.
Ketotifen
The risk or severity of thrombocytopenia can be increased when Empagliflozin is combined with Ketotifen.
L-Acetylleucine
The serum concentration of Linagliptin can be increased when it is combined with L-Acetylleucine.
Landiolol
Empagliflozin may increase the hypotensive activities of Landiolol.
Levodopa
The risk or severity of hypotension and orthostatic hypotension can be increased when Empagliflozin is combined with Levodopa.
Levothyroxine
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Levothyroxine.
Levothyroxine
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levothyroxine.
Linezolid
Linezolid may increase the hypoglycemic activities of Linagliptin.
Lithium carbonate
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lithium carbonate.
Lithium carbonate
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lithium carbonate.
Lofexidine
The risk or severity of adverse effects can be increased when Lofexidine is combined with Empagliflozin.
Loperamide
The excretion of Loperamide can be decreased when combined with Linagliptin.
Losartan
The risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.
Macitentan
Empagliflozin may increase the hypotensive activities of Macitentan.
Mannitol
Empagliflozin may increase the diuretic activities of Mannitol.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.
Methazolamide
The therapeutic efficacy of Linagliptin can be increased when used in combination with Methazolamide.
Methazolamide
Empagliflozin may increase the diuretic activities of Methazolamide.
Methyldopa
The risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.
Methyltestosterone
Methyltestosterone may increase the hypoglycemic activities of Empagliflozin.
Metolazone
Empagliflozin may increase the diuretic activities of Metolazone.
Metreleptin
The metabolism of Linagliptin can be increased when combined with Metreleptin.
Metyrosine
Empagliflozin may increase the hypotensive activities of Metyrosine.
Minoxidil
The risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.
Mitapivat
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Mitapivat.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Empagliflozin.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Empagliflozin.
Nandrolone decanoate
Nandrolone decanoate may increase the hypoglycemic activities of Linagliptin.
Nandrolone decanoate
Nandrolone decanoate may increase the hypoglycemic activities of Empagliflozin.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Empagliflozin.
Nitroglycerin
The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.
Nitroprusside
The risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.
Nitrous acid
The risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitrous acid.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Empagliflozin.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.
Opicapone
The risk or severity of adverse effects can be increased when Empagliflozin is combined with Opicapone.
Oxandrolone
Oxandrolone may increase the hypoglycemic activities of Linagliptin.
Oxandrolone
Oxandrolone may increase the hypoglycemic activities of Empagliflozin.
Oxymetholone
Oxymetholone may increase the hypoglycemic activities of Linagliptin.
Oxymetholone
Oxymetholone may increase the hypoglycemic activities of Empagliflozin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Empagliflozin.
Papaverine
The risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.
Phenelzine
Phenelzine may increase the hypoglycemic activities of Linagliptin.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Empagliflozin.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Empagliflozin.
Polythiazide
Empagliflozin may increase the diuretic activities of Polythiazide.
Potassium
Empagliflozin may increase the diuretic activities of Potassium.
Potassium cation
Empagliflozin may increase the diuretic activities of Potassium cation.
Potassium citrate
Empagliflozin may increase the diuretic activities of Potassium citrate.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Empagliflozin.
Prazosin
The risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.
Probenecid
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Probenecid.
Procaine
Procaine may increase the hypoglycemic activities of Linagliptin.
Procarbazine
Procarbazine may increase the hypoglycemic activities of Linagliptin.
Propofol
The metabolism of Linagliptin can be decreased when combined with Propofol.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Empagliflozin.
Quinupristin
The metabolism of Linagliptin can be decreased when combined with Quinupristin.
Rasagiline
Rasagiline may increase the hypoglycemic activities of Linagliptin.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Empagliflozin.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.
Riociguat
The risk or severity of adverse effects can be increased when Riociguat is combined with Empagliflozin.
Risperidone
Empagliflozin may increase the hypotensive activities of Risperidone.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Empagliflozin.
Rosuvastatin
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Rosuvastatin.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Empagliflozin.
Sacubitril
The risk or severity of adverse effects can be increased when Empagliflozin is combined with Sacubitril.
Selexipag
Empagliflozin may increase the hypotensive activities of Selexipag.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Empagliflozin.
Sildenafil
The risk or severity of hypotension can be increased when Sildenafil is combined with Empagliflozin.
Sotatercept
Empagliflozin may increase the hypotensive activities of Sotatercept.
Spironolactone
Empagliflozin may increase the diuretic activities of Spironolactone.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Empagliflozin.
Sulfamethizole
The therapeutic efficacy of Linagliptin can be increased when used in combination with Sulfamethizole.
Sulfamethizole
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sulfamethizole.
Sumatriptan
The therapeutic efficacy of Linagliptin can be increased when used in combination with Sumatriptan.
Sumatriptan
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Sumatriptan.
Tadalafil
Empagliflozin may increase the hypotensive activities of Tadalafil.
Talazoparib
The serum concentration of Talazoparib can be increased when it is combined with Linagliptin.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Empagliflozin.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.
Terazosin
The risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.
Testosterone
Testosterone may increase the hypoglycemic activities of Empagliflozin.
Testosterone cypionate
Testosterone cypionate may increase the hypoglycemic activities of Empagliflozin.
Testosterone enanthate
Testosterone enanthate may increase the hypoglycemic activities of Empagliflozin.
Testosterone propionate
Testosterone propionate may increase the hypoglycemic activities of Empagliflozin.
Testosterone undecanoate
Testosterone undecanoate may increase the hypoglycemic activities of Linagliptin.
Testosterone undecanoate
Testosterone undecanoate may increase the hypoglycemic activities of Empagliflozin.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Empagliflozin.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Empagliflozin.
Tipiracil
The excretion of Tipiracil can be decreased when combined with Linagliptin.
Tizanidine
The risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.
Tocopherylquinone
Empagliflozin may increase the hypotensive activities of Tocopherylquinone.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Empagliflozin.
Tolvaptan
Empagliflozin may increase the diuretic activities of Tolvaptan.
Torasemide
Empagliflozin may increase the diuretic activities of Torasemide.
Tranylcypromine
Tranylcypromine may increase the hypoglycemic activities of Linagliptin.
Treprostinil
Empagliflozin may increase the hypotensive activities of Treprostinil.
Triamterene
Empagliflozin may increase the diuretic activities of Triamterene.
Trofinetide
The metabolism of Linagliptin can be decreased when combined with Trofinetide.
Vadadustat
The serum concentration of Linagliptin can be increased when it is combined with Vadadustat.
Valdecoxib
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Valdecoxib.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.
Vardenafil
The risk or severity of hypotension can be increased when Vardenafil is combined with Empagliflozin.
Varenicline
The excretion of Varenicline can be decreased when combined with Linagliptin.
Vemurafenib
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Vemurafenib.
Vericiguat
The risk or severity of adverse effects can be increased when Empagliflozin is combined with Vericiguat.
Viloxazine
The metabolism of Linagliptin can be decreased when combined with Viloxazine.
Zonisamide
Empagliflozin may increase the diuretic activities of Zonisamide.